IL-17-induced inflammation modulates the mPGES-1/PPAR-γ pathway in monocytes/macrophages

Research output: Contribution to journalArticlepeer-review


  • Federica Raucci
  • Anella Saviano
  • Gian Marco Casillo
  • Miguel Guerra-Rodriguez
  • Adel Abo Mansour
  • Marialuisa Piccolo
  • Maria Grazia Ferraro
  • Elisabetta Panza
  • Valentina Vellecco
  • Carlo Irace
  • Francesco Caso
  • Raffaele Scarpa
  • Nicola Mascolo
  • Mohammed Alfaifi
  • Francesco Maione

Colleges, School and Institutes

External organisations

  • King Khalid University
  • University of Naples Federico II


Background and Purpose: Recent biochemical and pharmacological studies have reported that in several tissues and cell types, microsomal PGE 2 synthase (mPGES) and PPAR-γ expression are modulated by a variety of inflammatory factors and stimuli. Considering that very little is known about the biological effects promoted by IL-17 in the context of mPGES-1/PPAR-γ modulation, we sought to investigate the contribution of this unique cytokine on this integrated pathway during the onset of inflammation.

Experimental Approach: We evaluated effects of PF 9184 (mPGES-1 inhibitor) and troglitazone (PPAR-γ agonist) in vitro, using the mouse macrophage cell line J774A.1. In vivo, the dorsal air pouch model in CD1 mice was used, and inflammatory infiltrates were analysed by flow cytometry. Locally produced cyto-chemokines and PGs were assessed using elisa assays. Western blots were also employed to determine the activity of various enzymes involved in downstream signalling pathways.

Key Results: PF 9184 and troglitazone, in a time- and dose-dependent manner, modulated leukocyte infiltration, myeloperoxidase activity, and the expression of COX-2/mPGES-1, NF-кB/IкB-α, and mPTGDS-1/PPAR-γ, induced by IL-17. Moreover, both PF 9184 and troglitazone modulated PG (PGE 2, PGD 2, and PGJ 2) production, the expression of different pro-inflammatory cyto-chemokines, and the recruitment of inflammatory monocytes, in response to IL-17.

Conclusions and Implications: Our data suggest that IL-17 may constitute a specific modulator of inflammatory monocytes during later phases of the inflammatory response. The results of this study show, for the first time, that the IL-17/mPGES-1/PPAR-γ pathway could represent a potential therapeutic target for inflammatory-based and immune-mediated diseases.

Bibliographic note

Funding Information: This work was supported by MIUR (PRIN 2017; 2017A95NCJ/201795NCJ_002, “Stolen molecules ‐ Stealing natural products from the depot and reselling them as new drug candidates”) and Birmingham Fellowship awarded to A.J.I. Publisher Copyright: © 2021 The British Pharmacological Society


Original languageEnglish
JournalBritish Journal of Pharmacology
Early online date17 Feb 2021
Publication statusE-pub ahead of print - 17 Feb 2021


  • IL-17A, PGE, PPAR-γ, inflammation, mPGES-1, monocytes/macrophages

ASJC Scopus subject areas